{"id":37480,"date":"2024-12-09T09:49:07","date_gmt":"2024-12-09T08:49:07","guid":{"rendered":"https:\/\/www.resist-cluster.de\/?p=37480"},"modified":"2024-12-09T09:58:41","modified_gmt":"2024-12-09T08:58:41","slug":"vaccine-research-new-hope-in-the-fight-against-hepatitis-c","status":"publish","type":"post","link":"https:\/\/www.resist-cluster.de\/en\/vaccine-research-new-hope-in-the-fight-against-hepatitis-c\/","title":{"rendered":"Vaccine research: New hope in the fight against hepatitis C"},"content":{"rendered":"

The development of an effective vaccine against the Hepatitis C virus (HCV) has posed a significant challenge for decades due to the high genetic diversity of the virus. A research team led by Prof. Dr. Thomas Krey from the Institute of Biochemistry and the Center for Structural and Cell Biology in Medicine at the University of L\u00fcbeck, in collaboration with international partners, has now achieved a major breakthrough: using so-called \u201cepitope-focused immunogens,\u201d they were able to induce broadly neutralizing antibodies (bnAbs) in laboratory models for the first time. The promising results of the study were published in the renowned journal Science Advances<\/a>.<\/p>\n

Globally, approximately 58 million people are chronically infected with HCV, resulting in 290,000 annual deaths due to complications such as liver cirrhosis and liver cancer. Although modern antiviral treatments achieve high cure rates, the global elimination of HCV remains a difficult goal due to inadequate early detection and limited treatment options. Indeed, HCV has been identified as one of the globally prioritized endemic pathogens for vaccine research and development in the World Health Organization’s \u201cImmunization Agenda 2030.\u201d It is among the pathogens for which there is an urgent need for vaccines, as they cause a significant disease burden. An effective vaccine could fill this gap and limit the spread of the virus.<\/p>\n

The Innovative Approach of the Research<\/strong><\/p>\n

“Our research lays the foundation for a new generation of vaccines. We focus on overcoming the challenges posed by the viral diversity and immunological evasion of HCV,” explains Prof. Krey. The team employed novel computational protein designs to mimic specific regions of the viral glycoproteins E1 and E2, known as neutralization epitopes. These were transferred onto synthetic protein carriers and integrated into nanoparticles to elicit the most effective immune response possible. The study demonstrated that these epitope-focused immunogens in mouse models with a human antibody repertoire triggered a robust immune response. The produced antibodies were capable of successfully neutralizing multiple genetically diverse HCV strains.<\/p>\n

Potential for Vaccine Development<\/strong><\/p>\n

The results of this study provide a promising approach to overcoming previous failures in developing an effective HCV vaccine. \u201cThis proof-of-concept approach not only brings us closer to an effective HCV vaccine but could also set new standards in vaccine development against this and other medically significant viruses,\u201d says Dr. Kumar Nagarathinam, lead author of the study.<\/p>\n

The study represents a significant milestone in vaccine research and could contribute to limiting the global spread of Hepatitis C in the long term. Future research aims to further enhance the efficacy of the immunogens. Additionally, the insights gained could be applied to other viruses that pose similar challenges for vaccine development.<\/p>\n

Press release from the University of L\u00fcbeck<\/em><\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

Prof. Krey and his team published a study on an innovative vaccine design against the hepatitis C virus.<\/p>\n","protected":false},"author":4,"featured_media":4489,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[51],"tags":[],"class_list":["post-37480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts\/37480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/comments?post=37480"}],"version-history":[{"count":6,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts\/37480\/revisions"}],"predecessor-version":[{"id":37488,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts\/37480\/revisions\/37488"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/media\/4489"}],"wp:attachment":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/media?parent=37480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/categories?post=37480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/tags?post=37480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}